Emodin-induced apoptosis in human breast cancer BCap-37 cells through the mitochondrial signaling pathway
- First Online:
- 207 Downloads
Emodin, a natural anthraquinone compound isolated from the rhizome of rhubarb, is reported to suppress the growth of tumor in many clinical situations. In this study, we focused on the effect of emodin in human breast cancer BCap-37 cells and further understand the underlying molecular mechanism in treating breast cancer. Using MTT assay and flow cytometry, we demonstrated the critical role of emodin in the suppression of the proliferation of BCap-37 cells based on a concentration-and time-dependent manner. The increase of apoptotic rate was also observed after incubation of BCap-37 cells on emodin at 20 μM and 50 μM for 48 h. The cells exhibited typical apoptotic features including cellular morphological change, chromatin condensation and membrane blebbing. The results of the study further showed that Bcl-2 level decreased, while Bax and cytosolic cytochrome c levels in sample cells increased after the emodin treatment by using Western blot. The decline in the Bcl-2/Bax ratio and the increase of cytosolic cytochrome c concentration were consistent with the increase of the apoptotic ratio. The results strongly suggest that the disruption of the mitochondrial signaling pathway was involved in emodin-induced apoptosis in BCap-37 cells.
Key wordsEmodin Human breast cancer BCap-37 cells Apoptosis The mitochondrial signaling pathway
Unable to display preview. Download preview PDF.
- Brambilla, E., Negoescu, A., Gazzeri, S., Lantuejoul, S., Moro, D., Brambilla, C., and Coll, J. L., Apoptosis-related factors p53, Bcl2, and Bax in neuroendocrine lung tumors. Am. J. Pathol., 149, 941–1952 (1996).Google Scholar
- Chen, Y. C., Shen, S. C., Lee, W. R., Hsu, F. L., Lin, H. Y., Ko, C. H., and Tseng, S. W., Emodin induces apoptosis in human promyeleukemic HL60 cells accompanied by activation of caspase 3 cascade but independent of reactive oxygen species production. Biochem. Pharmacol., 64, 1713–1724 (2002).PubMedCrossRefGoogle Scholar
- Gazzaniga, P., Gradilone, A., Vercillo, R., Gandini, O., Silvestri, I., Napolitano, M., Albonici, L., Vincenzoni, A., Gallucci, M., Frati, L., and Agliano, A. M., Bcl-2/bax mRNA expression ratio as prognostic factor in low-grade urinary bladder cancer. Int. J. Cancer, 69, 100–104 (1996).PubMedCrossRefGoogle Scholar
- Jing Y, Yang, J., Wang, Y., Li, H., Chen, Y., Hu, Q., Shi, G., Tang, X., and Yi, J., Alteration of subcellular redox equilibrium and the consequent oxidative modification of nuclear factor êB are critical for anticancer cytotoxicity by emodin, a reactive oxygen species-producing agent. Free Radic. Biol. Med., 40, 2183–2197 (2006).PubMedCrossRefGoogle Scholar
- Kwak, H. J., Park, M. J., Park, C. M., Moon, S. I., Yoo, D. H., Lee, H. C., Lee, S. H., Kim. M. S., Lee, H. W., Shin, W. S., Park, I. C., Rhee, C. H., and Hong, S. I., Emodin inhibits vascular endothelial growth factor-A-induced angiogenesis by blocking receptor-2 (KDR/Flk-1) phosphorylation. Int. J. Cancer, 118, 2711–2720 (2006).PubMedCrossRefGoogle Scholar
- Muto, A., Hori, M., Sasaki, Y., Saitoh, A., Yasuda, I., Maekawa, T., Uchida, T., Asakura, K., Nakazato, T., Kaneda, T., Kizaki, M., Ikeda, Y., and Yoshida, T., Emodin has a cytotoxic activity against human multiple myeloma as a Janus-activated kinase 2 inhibitor. Mol. Cancer Ther., 6, 987–993 (2007).PubMedCrossRefGoogle Scholar
- Yang, J., Li, H., Chen, Y. Y., Wang, X. J., Shi, G. Y., Hu, Q. S., Kang, X. L., Lu, Y., Tang, X. M., Guo, Q. S., and Yi, J., Anthraquinones sensitize tumor cells to arsenic cytotoxicity in vitro and in vivo via reactive oxygen species-mediated dual regulation of apoptosis. Free Radic. Biol. Med., 37, 2027–2041 (2004).PubMedCrossRefGoogle Scholar